Joseph Shulman - Feb 1, 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: Chief Technical Officer
Signature: /s/ Hunter Smith, Attorney-in-Fact for Joseph Shulman
Stock symbol: RYTM
Transactions as of: Feb 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/3/2023, 03:09 PM
Previous filing: Feb 15, 2022
Next filing: Feb 14, 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RYTM	Restricted Stock Units	Award	$0	+15.8K		$0.00	15.8K	Feb 1, 2023	Common Stock	15.8K		Direct	F1, F2
transaction	RYTM	Stock Option (Right to Buy)	Award	$0	+33.5K		$0.00	33.5K	Feb 1, 2023	Common Stock	33.5K	$27.35	Direct	F3

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2	The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.
F3	The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.